TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > FDA 483 Observations Relating to Cleaning

FDA 483 Observations Relating to Cleaning

The requirement for clean equipment has long been part of FDA requirements since the 1963 GMP Regulations (Part 133.4) stating as follows “Equipment *** shall be maintained in a clean and orderly manner ***.” In the 1978 cGMP regulations, a very similar section on equipment cleaning (211.67) was included. FDA investigators have always looked for gross insanitation due to inadequate cleaning and maintenance of equipment and/or poor dust control systems. It continues to be a focus for inspectors. At the beginning of each federal fiscal year, the US FDA posts the previous year’s Form 483 observation metrics issued by each product center. The 2016 Fiscal Year top 5 observations reported by the Drug sector are:

  • Procedures applicable to the quality control unit are not in writing and/or not fully followed
  • Laboratory controls are not scientifically sound and appropriate
  • Failure to thoroughly review unexplained discrepancies
  • Lack of written procedures for production and process controls
  • Written procedures are not followed for the cleaning/maintenance of equipment and utensils

Here are some specific examples from the past two years.

  1. The FDA issued a Form 483 to a New Jersey based facility over cleaning, sanitation and quality control issues after an October 2017 inspection.

The investigator noted inadequate methods for cleaning and maintaining equipment. For example, a dirty rag was found inside the firm’s tablet press, and a yellow powder was found on equipment in the firm’s coating room, though the last product on the production line was white in color. Written procedures for cleaning and maintaining equipment and utensils used in the manufacturing of drug products were not followed, according to the report. Metal detectors were observed without cleaning procedures and safety instructions. In addition, devices were not fully covered in an equipment storage room, a stainless steel scoop did not have a bag, and there were no cleaning procedures for multiple items in the room. The agency also observed sanitation issues during the inspection. The investigator found a dead insect on the floor of the facility’s pharmacy room, and determined that complete cleaning was not possible because of rusted filing cabinets, packaging components and various materials throughout the room.   2.    In February 23, 2016 a form 483 was issued to a drug manufacturing facility citing cleaning procedures as follows: Cleaning Procedures: There is no assurance that your cleaning and sanitization methods are adequate …………Cleaning and sanitizing procedures for kettles, vessels, and transfer pumps lack detailed instructions. This is particularly important for your product mix in that the insolubility of some excipients and active ingredients makes equipment difficult to clean, and could result in cross-contamination between your products. No cleaning procedures were established for the (b)(4) production equipment used to fill topical drug products *********.As mentioned in Charge 1, lot (b)(4) failed microbial testing. In your response to the FDA 483, you provided an updated Master Cleaning Validation Plan. You will use a matrix approach to update your procedures. However, you provided insufficient detail for us to determine the adequacy of your new plan, or the effectiveness of your plans for products already manufactured on inadequately cleaned equipment. In your response to this letter, please provide a detailed cleaning validation plan, including cleaning agent concentrations, hold times before cleaning, equipment disassembly instructions, cleaning frequencies, rinse times, and water temperatures; timeframes for completing your Master Cleaning Validation Plan; and a summary of your interim plan to ensure the quality of drugs that you continue to manufacture and distribute before you complete your corrective action and cleaning validation activities.” 3.   Early in 2017, a Warning Letter was issued by the FDA citing Inadequate Cleaning Validation to an API manufacturing facility. Among the problems that FDA inspection noted were:

  •  Inadequate cleaning and contamination prevention measures.
  •  Failure to ensure compliance with cGMPs regarding material testing
  •   Insufficient quality requirements for batch release.

Manufacturing equipment was found to contain rust and insects, while some pieces were damaged, and drug residue was found on equipment surfaces, suggesting that product batches were contaminated with small levels of previous batches of other APIs. The company’s corrective and preventive action plans were inadequate, FDA inspectors said, because they did not outline cleaning procedures and equipment maintenance procedures in detail. FDA asked for assurance of cleanliness, as well as evidence of thorough cleaning validation tests, maintenance programs, and risk assessment of released batches. If you would like assistance with your cleaning validation process  –  please connect with us  +353 1 846 47 42 or contactirl@pharmalex.com.

Related posts
Resilience of Pharma Supply Chains and the Impact of Covid-19 Pandemic
Resilience of Pharma Supply Chains and the Impact of Covid-19 Pandemic
17th May 2021
Contamination Control
Contamination Control
8th April 2021
Rules on Ownership of Medicinal Product stock distributed in Great Britain
Rules on Ownership of Medicinal Product stock distributed in Great Britain
7th April 2021
GET SMART: reliable analytical results & continuous regulatory compliance!
GET SMART: reliable analytical results & continuous regulatory compliance!
30th March 2021
Challenges of Advanced Therapy Medicinal Products (ATMPs)
Challenges of Advanced Therapy Medicinal Products (ATMPs)
16th March 2021
Supporting M&A in the pharmaceutical / biopharmaceutical industry
Supporting M&A in the pharmaceutical / biopharmaceutical industry
11th February 2021
Search
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Upcoming Events

June 23rd, 2022

PDA Ireland: Data Integrity

June 19 - 23rd, 2022

DIA 2022 – Reconnect with Your Life Sciences Community Live in Chicago

Visit us at booth #1515

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
8 Jun

Mark A Lane, PhD latest blog here https://lnkd.in/ejDdywz3 explores Integrated Product Development approaches to accelerate drug development.

To find out more register for our IPD webinar https://lnkd.in/eijUBJM5

#pharmadrugdevelopment
#webinar
#biopharmaceutical

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Highly competent, knowledgeable, absolutely reliable and dedicated to the projects

    Europe based medium-sized biotech development company
    Senior Director
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for